Related Experiment Video

Updated: Mar 29, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics

Silvia Lovera1, Maria Morando2, Encarna Pucheta-Martinez1

  • 1Department of Chemistry, University College London, London, United Kingdom.

Plos Computational Biology
|November 26, 2015
PubMed

Insights

Imatinib resistance in chronic myeloid leukemia is a major concern. This study reveals how Abl kinase mutations alter protein dynamics, leading to drug resistance and impacting treatment efficacy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Imatinib is highly effective for chronic myeloid leukemia (CML) by inhibiting the BCR-ABL fusion protein.
  • Drug resistance, driven by mutations in the Abl kinase domain, limits imatinib's long-term efficacy.
  • The precise molecular mechanisms underlying imatinib resistance mutations remain incompletely understood.

Purpose of the Study:

  • To elucidate the molecular mechanisms of drug-resistant Abl kinase mutations.
  • To compare the conformational dynamics of wild-type Abl with drug-resistant mutants.
  • To investigate the impact of mutations on protein function and drug binding.

Main Methods:

  • Long molecular dynamics simulations.
  • Large-scale free energy calculations.
  • In vitro mutagenesis and microcalorimetry experiments.

Main Results:

  • Drug-resistant mutations cause significant alterations in the inactive-to-active conformational dynamics of Abl kinase.
  • Key functional elements, including the activation loop and DFG motif, exhibit altered entropy/enthalpy balances in mutants.
  • The T315I gatekeeper mutation profoundly affects imatinib binding mechanism and kinetics.

Conclusions:

  • The study clarifies the molecular basis of imatinib resistance in Abl kinase.
  • Understanding these mutation-driven dynamics is crucial for developing next-generation CML therapies.
  • Targeting specific conformational changes or binding kinetics could overcome resistance.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K